COEP (Coeptis Therapeutics Holdings) Loans Receivable: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COEP Coeptis Therapeutics Holdings Inc COEP
12 GF Score
Price $16.40
View Full Analysis

What is Coeptis Therapeutics Holdings Loans Receivable?

Coeptis Therapeutics Holdings COEP +1.52% 12 Loans Receivable is $0.00 Mil as of Dec. 2025. GuruFocus rates COEP with a GF Score™ of 12/100.

Coeptis Therapeutics Holdings's Loans Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Coeptis Therapeutics Holdings Loans Receivable Related Terms

Coeptis Therapeutics Holdings Loans Receivable Historical Data

* Premium members only.

The historical data trend for Coeptis Therapeutics Holdings's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coeptis Therapeutics Holdings Loans Receivable Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Coeptis Therapeutics Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
COEP
12GF Score
Coeptis Therapeutics Holdings Inc COEP
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coeptis Therapeutics Holdings Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Coeptis Therapeutics Holdings (COEP) has a Loans Receivable of $0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Coeptis Therapeutics Holdings and its competitors.
Is Coeptis Therapeutics Holdings' Loans Receivable too high?
Coeptis Therapeutics Holdings' current Loans Receivable is $0.00 Mil. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' Loans Receivable compare to ANIX and COYA?
Coeptis Therapeutics Holdings' Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Coeptis Therapeutics Holdings and its competitors. Coeptis Therapeutics Holdings's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current Loans Receivable is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score

Get the complete analysis for COEP

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40
Price